|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9673
|
|
pubmed:dateCreated |
2009-4-27
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Most patients admitted for acute heart failure have normal or increase blood pressure. Relaxin is a natural human peptide that affects multiple vascular control pathways, suggesting potential mechanisms of benefit for such patients. We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:CotterGadG,
pubmed-author:FelkerG MichaelGM,
pubmed-author:GrzybowskiJacekJ,
pubmed-author:KatzAmosA,
pubmed-author:MarmorAlonA,
pubmed-author:MetraMarcoM,
pubmed-author:PonikowskiPiotrP,
pubmed-author:TeerlinkJohn RJR,
pubmed-author:TeichmanSam LSL,
pubmed-author:UnemoriElaineE,
pubmed-author:VoorsAdriaan AAA,
pubmed-author:WeatherleyBeth DavisonBD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
25
|
|
pubmed:volume |
373
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1429-39
|
|
pubmed:meshHeading |
pubmed-meshheading:19329178-Acute Disease,
pubmed-meshheading:19329178-Aged,
pubmed-meshheading:19329178-Aged, 80 and over,
pubmed-meshheading:19329178-Dose-Response Relationship, Drug,
pubmed-meshheading:19329178-Double-Blind Method,
pubmed-meshheading:19329178-Female,
pubmed-meshheading:19329178-Follow-Up Studies,
pubmed-meshheading:19329178-Heart Failure,
pubmed-meshheading:19329178-Humans,
pubmed-meshheading:19329178-Hypertension,
pubmed-meshheading:19329178-Infusions, Intravenous,
pubmed-meshheading:19329178-Male,
pubmed-meshheading:19329178-Middle Aged,
pubmed-meshheading:19329178-Relaxin,
pubmed-meshheading:19329178-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
|
|
pubmed:affiliation |
Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
